(MedPage Today) -- A reassessment of the results of the RECORD trial by independent reviewers has turned up similar results to the initial report, possibly signaling new life for the embattled diabetes drug rosiglitazone (Avandia), according to FDA documents. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment